{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:08:32Z","timestamp":1777950512644,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10549-026-07954-0","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:45:34Z","timestamp":1774943134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of endpoints in phase 3 randomized controlled trials in metastatic breast cancer"],"prefix":"10.1007","volume":"217","author":[{"given":"Weronika","family":"Kupis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"K\u0142osowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Harhala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Seku\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Pogoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-1959","authenticated-orcid":false,"given":"Jan","family":"Borysowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"10512","key":"7954_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","volume":"406","author":"GBD 2023 Cancer Collaborators","year":"2025","unstructured":"GBD 2023 Cancer Collaborators (2025) The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406(10512):1565\u20131586. https:\/\/doi.org\/10.1016\/S0140-6736(25)01635-6","journal-title":"Lancet"},{"issue":"4","key":"7954_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clbc.2021.01.017","volume":"21","author":"K Daily","year":"2021","unstructured":"Daily K, Douglas E, Romitti PA, Thomas A (2021) Epidemiology of de novo metastatic breast cancer. Clin Breast Cancer 21(4):302\u2013308. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.017","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"7954_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01881-y","volume":"26","author":"E Morgan","year":"2024","unstructured":"Morgan E, O\u2019Neill C, Shah R, Langselius O, Su Y, Frick C, Fink H, Bardot A, Walsh PM, Woods RR, Gonsalves L, Nyg\u00e5rd JF, Negoita S, Ramirez-Pena E, Gelmon K, Antone N, Mutebi M, Siesling S, Cardoso F, Gralow J, Soerjomataram I, Arnold M (2024) Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer Res 26(1):171. https:\/\/doi.org\/10.1186\/s13058-024-01881-y","journal-title":"Breast Cancer Res"},{"key":"7954_CR4","unstructured":"Food and Drug Administration. Approaches to assessment of overall survival in oncology clinical trials. Draft guidance for industry. 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/approaches-assessment-overall-survival-oncology-clinical-trials. Accessed 9 Sept 2025."},{"key":"7954_CR5","unstructured":"Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. Guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics Accessed 12 Sept 2025."},{"issue":"5","key":"7954_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","volume":"7","author":"JC Del Paggio","year":"2021","unstructured":"Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM (2021) Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol 7(5):728\u2013734. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0379","journal-title":"JAMA Oncol"},{"issue":"32","key":"7954_CR7","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.18.00242","volume":"36","author":"AD Seidman","year":"2018","unstructured":"Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA (2018) National Cancer Institute Breast Cancer Steering Committee Working Group report on meaningful and appropriate end points for clinical trials in metastatic breast cancer. J Clin Oncol 36(32):3259\u20133268. https:\/\/doi.org\/10.1200\/JCO.18.00242","journal-title":"J Clin Oncol"},{"issue":"11","key":"7954_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.18553\/jmcp.2022.28.11.1219","volume":"28","author":"O Alabaku","year":"2022","unstructured":"Alabaku O, Laffey TN, Suh K, Li M (2022) Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021. J Manag Care Spec Pharm 28(11):1219\u20131223. https:\/\/doi.org\/10.18553\/jmcp.2022.28.11.1219","journal-title":"J Manag Care Spec Pharm"},{"key":"7954_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2022.100364","volume":"34","author":"A Walia","year":"2022","unstructured":"Walia A, Haslam A, Prasad V (2022) FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy 34:100364. https:\/\/doi.org\/10.1016\/j.jcpo.2022.100364","journal-title":"J Cancer Policy"},{"key":"7954_CR10","unstructured":"International Clinical Trials Registry Platform. World Health Organization. https:\/\/www.who.int\/tools\/clinical-trials-registry-platform. Accessed 11 Sept 2025."},{"issue":"16","key":"7954_CR11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.23.01777","volume":"42","author":"H Xiao","year":"2024","unstructured":"Xiao H, Vaidya R, Hershman DL, Unger JM (2024) Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials: time series analyses for 2012-2022. J Clin Oncol 42(16):1953\u20131960. https:\/\/doi.org\/10.1200\/JCO.23.01777","journal-title":"J Clin Oncol"},{"issue":"1","key":"7954_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02947-y","volume":"21","author":"K Szlezinger","year":"2023","unstructured":"Szlezinger K, Pogoda K, Jagie\u0142\u0142o-Gruszfeld A, K\u0142osowska D, G\u00f3rski A, Borysowski J (2023) Eligibility criteria in clinical trials in breast cancer: a cohort study. BMC Med 21(1):240. https:\/\/doi.org\/10.1186\/s12916-023-02947-y","journal-title":"BMC Med"},{"key":"7954_CR13","unstructured":"R Core Team (2024) R: a language and environment for statistical computing. https:\/\/www.R-project.org\/"},{"issue":"1","key":"7954_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5(1):5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"7954_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tr\u00e9dan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O\u2019Shaughnessy J, Pivot X, Tolaney SM, Hurvitz SA, Llombart-Cussac A, Andr\u00e9 V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD (2024) Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 35(8):718\u2013727. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.013","journal-title":"Ann Oncol"},{"key":"7954_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","volume":"136","author":"D Pasalic","year":"2020","unstructured":"Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, R\u00f6del C, Thomas CR Jr, Minsky BD, Ludmir EB (2020) Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer 136:176\u2013185. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.015","journal-title":"Eur J Cancer"},{"issue":"8","key":"7954_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A (2015) The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 175(8):1389\u20131398. https:\/\/doi.org\/10.1001\/jamainternmed.2015.2829","journal-title":"JAMA Intern Med"},{"key":"7954_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/BCTT.S162841","volume":"10","author":"A Forsythe","year":"2018","unstructured":"Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G (2018) Progression-free survival\/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer. Breast Cancer (Dove Med Press) 10:69\u201378. https:\/\/doi.org\/10.2147\/BCTT.S162841","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"7954_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clbc.2017.07.015","volume":"18","author":"L Li","year":"2018","unstructured":"Li L, Pan Z (2018) Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials. Clin Breast Cancer 18(1):63\u201370. https:\/\/doi.org\/10.1016\/j.clbc.2017.07.015","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"7954_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-020-05615-4","volume":"181","author":"T Hirai","year":"2020","unstructured":"Hirai T, Nemoto A, Ito Y, Matsuura M (2020) Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer. Breast Cancer Res Treat 181(1):189\u2013198. https:\/\/doi.org\/10.1007\/s10549-020-05615-4","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"7954_CR21","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, L\u00fcck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26(12):1987\u20131992. https:\/\/doi.org\/10.1200\/JCO.2007.10.8407","journal-title":"J Clin Oncol"},{"issue":"10","key":"7954_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101791","volume":"16","author":"M Kesireddy","year":"2024","unstructured":"Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, Krishnamurthy J (2024) Overall survival and prognostic factors in metastatic triple-negative breast cancer: a National Cancer Database analysis. Cancers (Basel) 16(10):1791. https:\/\/doi.org\/10.3390\/cancers16101791","journal-title":"Cancers (Basel)"},{"issue":"7","key":"7954_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/pon.5054","volume":"28","author":"A Shrestha","year":"2019","unstructured":"Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L (2019) Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology 28(7):1367\u20131380. https:\/\/doi.org\/10.1002\/pon.5054","journal-title":"Psychooncology"},{"issue":"7","key":"7954_CR24","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/ijc.31957","volume":"144","author":"TJ Hwang","year":"2019","unstructured":"Hwang TJ, Gyawali B (2019) Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials. Int J Cancer 144(7):1746\u20131751. https:\/\/doi.org\/10.1002\/ijc.31957","journal-title":"Int J Cancer"},{"issue":"8","key":"7954_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","volume":"36","author":"NI Cherny","year":"2025","unstructured":"Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, Gyawali B, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, de Vries EGE (2025) ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Ann Oncol 36(8):866\u2013908. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.006","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07954-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07954-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07954-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:36:22Z","timestamp":1777880182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07954-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7954"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07954-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.P.: honoraria: AstraZeneca, Gilead, Eli Lilly, MSD, Roche, Pfizer, Egis, Teva, Novartis; fee conference support: Gilead, Astra Zeneca, Eli Lilly; contracted research: AstraZeneca, Roche, Eli Lilly, Novartis, GlaxoSmithKline, Pfizer. W.K., D.K., M.H., M.S., and J.B. have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"6"}}